News + Publications

Recent News

DNARx Awarded DARPA Contract for up to $10.7 Million to Develop Non-Viral DNA-Encoded Gene Therapy to Protect Against Pandemic Influenza

DNARx’s proprietary HEDGES™ non-viral gene therapy delivery platform promises rapid, reliable, low-cost and relatively simple manufacturing and delivery of gene vectors to treat a wide range of diseases, particularly as compared to currently-employed delivery of genes using viruses.

Read More